Protocol Summaries: GSK2130579A(Primary)
| GSK Study ID |
Phase | Title | Status |
|---|---|---|---|
| 111444 | phase 1 | Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as post-consolidation therapy in adult patients in first complete remission | Active not recruiting |